You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the RADICAVA (edaravone) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR RADICAVA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for RADICAVA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03272503 ↗ A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) Recruiting ALS Canada Phase 2 2017-10-27 This study will look at whether Pimozide may help to slow the progression of Amyotrophic Lateral Sclerosis. 100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2 groups. The first group will receive a dose of up to 2mg of Pimozide per day and the second group will receive placebo (lactose tablets). Subjects will be assigned randomly (like by a flip of a coin) to receive either Pimozide 2 mg per day or placebo tablets. There will be a fifty-fifty chance of receiving Pimozide or placebo. Participants will be on study medication up to 22 weeks, and on study up to 26 weeks. There are 8 clinic visits and 1 phone visit over the course of the Treatment Phase of the study. The second phase which is Observational, is optional with follow-up for up to 5 years from the end of the Treatment Phase.
NCT03272503 ↗ A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) Recruiting Brain Canada Phase 2 2017-10-27 This study will look at whether Pimozide may help to slow the progression of Amyotrophic Lateral Sclerosis. 100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2 groups. The first group will receive a dose of up to 2mg of Pimozide per day and the second group will receive placebo (lactose tablets). Subjects will be assigned randomly (like by a flip of a coin) to receive either Pimozide 2 mg per day or placebo tablets. There will be a fifty-fifty chance of receiving Pimozide or placebo. Participants will be on study medication up to 22 weeks, and on study up to 26 weeks. There are 8 clinic visits and 1 phone visit over the course of the Treatment Phase of the study. The second phase which is Observational, is optional with follow-up for up to 5 years from the end of the Treatment Phase.
NCT03272503 ↗ A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) Recruiting University of Calgary Phase 2 2017-10-27 This study will look at whether Pimozide may help to slow the progression of Amyotrophic Lateral Sclerosis. 100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2 groups. The first group will receive a dose of up to 2mg of Pimozide per day and the second group will receive placebo (lactose tablets). Subjects will be assigned randomly (like by a flip of a coin) to receive either Pimozide 2 mg per day or placebo tablets. There will be a fifty-fifty chance of receiving Pimozide or placebo. Participants will be on study medication up to 22 weeks, and on study up to 26 weeks. There are 8 clinic visits and 1 phone visit over the course of the Treatment Phase of the study. The second phase which is Observational, is optional with follow-up for up to 5 years from the end of the Treatment Phase.
NCT03272802 ↗ Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) Unknown status Isfahan University of Medical Sciences Phase 2/Phase 3 2017-03-16 Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes the death of 30,000 affected individual every year. Complex nature and unknown pathogenesis of this disease are 2 major reasons for failure of therapeutic interventions. Edaravone is a free radical scavenger that slows down functional decline and prevents from disease progression in ALS patients. FDA newly approved this drug in these patients (2017/5/5). In this study, investigators aimed to assess the treatment effect of this newly approved drug in patients with ALS in a representative Iranian population.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for RADICAVA

Condition Name

Condition Name for RADICAVA
Intervention Trials
ALS 1
Amyotrophic Lateral Sclerosis 1
Healthy 1
Neuromuscular Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for RADICAVA
Intervention Trials
Motor Neuron Disease 2
Amyotrophic Lateral Sclerosis 2
Sclerosis 2
Liver Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for RADICAVA

Trials by Country

Trials by Country for RADICAVA
Location Trials
Canada 4
Slovakia 1
Hungary 1
Czechia 1
Iran, Islamic Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for RADICAVA

Clinical Trial Phase

Clinical Trial Phase for RADICAVA
Clinical Trial Phase Trials
Phase 2/Phase 3 1
Phase 2 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for RADICAVA
Clinical Trial Phase Trials
Unknown status 1
Completed 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for RADICAVA

Sponsor Name

Sponsor Name for RADICAVA
Sponsor Trials
ALS Canada 1
Brain Canada 1
University of Calgary 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for RADICAVA
Sponsor Trials
Other 4
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.